Mohammad RM - Search Results

1

Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.

Taub JW, Huang X, Ge Y, Dutcher JA, Stout ML, Mohammad RM, Ravindranath Y, Matherly LH. Taub JW, et al. Among authors: mohammad rm. Cancer Res. 2000 Nov 15;60(22):6421-6. Cancer Res. 2000. PMID: 11103808

2

A human B-cell lymphoma line with a de novo multidrug resistance phenotype.

Mohammad RM, Mohamed AN, KuKuruga M, Smith MR, al-Katib A. Mohammad RM, et al. Cancer. 1992 Mar 15;69(6):1468-74. doi: 10.1002/1097-0142(19920315)69:6<1468::aid-cncr2820690626>3.0.co;2-8. Cancer. 1992. PMID: 1540884

3

Induced expression of a ubiquitin COOH-terminal hydrolase in acute lymphoblastic leukemia.

al-Katib AM, Mohammad RM, Maki A, Smith MR. al-Katib AM, et al. Among authors: mohammad rm. Cell Growth Differ. 1995 Feb;6(2):211-7. Cell Growth Differ. 1995. PMID: 7756180

4

Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.

Mohammad RM, al-Katib A, Pettit GR, Sensenbrenner LL. Mohammad RM, et al. Cancer Res. 1994 Jan 1;54(1):165-8. Cancer Res. 1994. PMID: 8261437

5

Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.

Mohammad RM, Katato K, Almatchy VP, Wall N, Liu KZ, Schultz CP, Mantsch HH, Varterasian M, al-Katib AM. Mohammad RM, et al. Clin Cancer Res. 1998 Feb;4(2):445-53. Clin Cancer Res. 1998. PMID: 9516935

6

An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies.

Mohammad RM, Al-Katib A, Pettit GR, Vaitkevicius VK, Joshi U, Adsay V, Majumdar AP, Sarkar FH. Mohammad RM, et al. Clin Cancer Res. 1998 Apr;4(4):887-94. Clin Cancer Res. 1998. PMID: 9563882

7

Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.

Al-Katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B, Mohammad RM. Al-Katib AM, et al. Among authors: mohammad rm. Clin Cancer Res. 1998 May;4(5):1305-14. Clin Cancer Res. 1998. PMID: 9607591

8

Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.

Mohammad RM, Varterasian ML, Almatchy VP, Hannoudi GN, Pettit GR, Al-Katib A. Mohammad RM, et al. Clin Cancer Res. 1998 May;4(5):1337-43. Clin Cancer Res. 1998. PMID: 9607595

9

Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.

Ahmad I, Al-Katib AM, Beck FW, Mohammad RM. Ahmad I, et al. Among authors: mohammad rm. Clin Cancer Res. 2000 Apr;6(4):1328-32. Clin Cancer Res. 2000. PMID: 10778958

10

The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.

Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. Mohammad RM, et al. Clin Cancer Res. 2000 Dec;6(12):4950-6. Clin Cancer Res. 2000. PMID: 11156256

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

218 results

Search Page

Filters